Posted by Michael Wonder on 11 May 2018
Lynparza (olaparib) receives new indication for BRCA-mutated metastatic breast cancer
10 May 2018 - Lynparza has been shown to reduce the risk of disease progression or death by 42% compared to standard of care chemotherapy.
AstraZeneca today announced that Health Canada has approved Lynparza (olaparib) tablets, as a monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neo-adjuvant, adjuvant or metastatic setting. Patients with hormone receptor positive (HR+) breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before Lynparza treatment is initiated.ii
Health Canada’s approval of Lynparza for gBRCAm HER2-negative metastatic breast cancer was based on data from the phase III, randomized, open-label, multicentre, active-controlled trial, OlympiAD (Study D0819C00003).
